[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639094":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":24,"locations":24,"responsibleParty":41,"collaborators":24,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":24,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":24,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":24,"overallStatus":65,"whyStopped":24,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":24},{"fullName":5,"class":6},"Jiangmen Central Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Low-Dose Radiotherapy + EP\u002FEC + Adebrelimab","EXPERIMENTAL","All patients will first receive low-dose radiotherapy. Within one week after completion of radiotherapy, patients will receive concurrent systemic chemotherapy (either EP or EC regimen) combined with adebrelimab for 4-6 cycles. Following the 4-6 cycles of chemo-immunotherapy, patients will continue maintenance therapy with adebrelimab for up to two years.",[13,14,15,16,17],"Drug: Etoposide","Drug: Cisplatin","Drug: Carboplatin","Drug: Adebrelimab","Radiation: Thoracic Radiotherapy",[19,25,28,32,36],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Etoposide","Etoposide 100 mg\u002Fm² intravenously on days 1-3, plus Cisplatin 75 mg\u002Fm² intravenously on day 1, repeated every 21 days (q3w).",[9],null,{"type":20,"name":26,"description":22,"armGroupLabels":27,"otherNames":24},"Cisplatin",[9],{"type":20,"name":29,"description":30,"armGroupLabels":31,"otherNames":24},"Carboplatin","Etoposide 100 mg\u002Fm² intravenously on days 1-3, plus Carboplatin area under the curve (AUC) 5 intravenously on day 1, repeated every 21 days (q3w).",[9],{"type":20,"name":33,"description":34,"armGroupLabels":35,"otherNames":24},"Adebrelimab","20 mg\u002Fkg intravenously on day 1, repeated every 21 days (q3w). Administered concurrently with chemotherapy for 4-6 cycles, followed by maintenance monotherapy for up to 2 years.",[9],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":24},"RADIATION","Thoracic Radiotherapy","Radiotherapy will be delivered to the primary tumor in the lung, involved regional lymph nodes, and metastatic pleural lesions.",[9],{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Lin Xiao","Deputy Director of the Oncology Department","100639094","phase-2-low-dose-thoracic-radiotherapy-followed-by-adebrelimab-plus-chemotherapy-and-then-sequential-maintenance-therapy-with-adebrelimab-for-extensive-stage-small-cell-lung-cancer-100639094",false,"NCT07583550","Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer","Efficacy and Safety of Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy and Sequential Adebrelimab Maintenance Therapy for Extensive-stage Small Cell Lung Cancer: A Prospective, Multicenter Phase II Study","Inclusion Criteria:\n\n1. Age ≥18 years and ≤75 years.\n2. Histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC).\n3. No prior systemic anti-tumor therapy.\n4. ECOG performance status 0-2 and life expectancy ≥12 weeks.\n5. At least one measurable lesion per RECIST version 1.1.\n6. No brainstem metastasis and no significant neurological symptoms from brain metastases.\n7. All participants must undergo routine contrast-enhanced CT of the chest and upper abdomen, as well as brain MRI, before enrollment. Whole-body PET-CT plus brain MRI is preferred. For participants with limited financial resources who also have significant obstructive pneumonia or atelectasis, an additional chest MRI is recommended.\n8. No malignant pleural effusion or pericardial effusion.\n9. All participants must provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of interstitial pneumonia or infectious fever prior to treatment.\n2. Comorbid autoimmune diseases or long-term oral corticosteroid use (including those who received oral corticosteroids within 14 days prior to treatment).\n3. Prior history of thoracic radiotherapy or thoracic surgery.\n4. Presence of Grade ≥3 hematologic toxicity or hepatic\u002Frenal impairment.\n5. Hypersensitivity to adebrelimab.\n6. Significant respiratory symptoms that preclude tolerance to radiotherapy.\n7. Active hepatitis B or hepatitis C infection with ongoing antiviral therapy. Subjects with a documented history of HBV infection who have achieved undetectable HBV levels after prior active treatment at the time of enrollment may be included.\n8. Presence of pleural effusion or pericardial effusion.","ALL","18 Years","75 Years",{"count":56,"type":57},43,"ESTIMATED","INTERVENTIONAL",[60],"PHASE2","This multicenter, prospective study aims to investigate the efficacy and safety of low-dose radiotherapy (15Gy\u002F1.5 Gy bid × 10 fractions) combined with 4-6 cycles of systemic chemotherapy plus anti-PD-L1 antibody, followed by anti-PD-L1 antibody maintenance for up to two years, in participants with extensive-stage small cell lung cancer (ES-SCLC).\n\nAdditionally, dynamic monitoring using next-generation sequencing (NGS) technology will be performed to assess ctDNA levels, genetic information, and mutation abundance at the following time points: before and after low-dose radiotherapy, after 4-6 cycles of chemotherapy plus anti-PD-L1 antibody (chemotherapy-immunotherapy), and before the initiation of anti-PD-L1 maintenance therapy. This approach aims to guide efficacy and prognosis prediction, as well as to identify potential biomarkers associated with treatment response.",[63,64],"Lung","Radiotherapy","NOT_YET_RECRUITING","2026-05-06",{"date":68,"type":69},"2026-05-13","ACTUAL",{"date":71,"type":57},"2026-05-01",{"date":73,"type":57},"2028-01-01",{"name":5,"class":6}]